QOL Medical, LLC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$6.6M
Doctors Paid
13,238
Transactions
84,171
2024 Total
$1.9M
Payment Breakdown by Category
Research$3.5M (52.4%)
Food & Beverage$1.6M (24.7%)
Consulting$122,688 (1.9%)
Travel$75,034 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.5M | 291 | 52.4% |
| Food and Beverage | $1.6M | 82,486 | 24.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $934,599 | 542 | 14.1% |
| Honoraria | $321,052 | 279 | 4.9% |
| Consulting Fee | $122,688 | 28 | 1.9% |
| Travel and Lodging | $75,034 | 502 | 1.1% |
| Space rental or facility fees (teaching hospital only) | $32,500 | 12 | 0.5% |
| Grant | $25,000 | 1 | 0.4% |
| Compensation for serving as faculty or as a speaker for a medical education program | $2,500 | 1 | 0.0% |
| Education | $507.28 | 29 | 0.0% |
Payments by Type
Research
$3.5M
291 transactions
General
$3.1M
83,880 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| QOL Pediatric Sucraid | $1.4M | 0 | 143 |
| A Study of the Association of Genetic Sucrase-Isomaltase Deficiency (GSID) Allele Frequencies from Formalin Fixed Paraffin Embedded (FFPE) Tissue Samples with Low Sucrase Activity/DAR | $792,749 | 0 | 10 |
| Congenital Sucrase Isomaltase Deficiency (CSID) Screening Study in Adults > 18 years | $478,066 | 0 | 18 |
| Sucrase-Isomaltase Deficiency in Irritable Bowel Syndrome and Diarrhea - Hiding in Plain Sight? | $237,457 | 0 | 38 |
| FFPE/DAR | $122,567 | 0 | 6 |
| An Adult Pilot Study to Establish the Reference Ranges and Optimal Cut-offs for the Oral 50g Sucrose Challenge Test and the 13C-Sucrose Breath Test for CSID Cases (Previously Diagnosed Sucraid Responders) and Controls (GI Asymptomatic Healthy Volunteers) | $105,770 | 0 | 8 |
| QOL Fructan | $81,025 | 0 | 4 |
| Evaluation of a 7-Day Therapeutic Trial Dose of Commercial Sucraid (sacrosidase) Oral Solution for Alleviating Congenital Sucrase-Isomaltase Deficiency (CSID) Symptoms in Pediatric Subjects with Low, Moderate, and Normal Sucrase Levels | $55,440 | 0 | 10 |
| Prospective evaluation of the prevalence of sucrose malabsorption in patients referred for testing for small intestinal bacterial overgrowth | $53,115 | 0 | 22 |
| SSDXA-14 | $44,049 | 0 | 1 |
| Functional sucrase deficiency in short bowel syndrome patients with intestinal failure | $23,483 | 0 | 3 |
| C13 TESTING FOR SIBO PATIENTS | $17,468 | 0 | 11 |
| A Multi Center Study of the Prevalence of Known Congenital Sucrase Isomaltase Deficiency (CSID) Genetic Variants and Functional Sucrase Activity by 13C Sucrose Breath Test in Children with Chronic Diarrhea or Chronic Abdominal Pain | $14,176 | 0 | 3 |
| An Adult Pilot Study to Establish the Reference Ranges and Optimal Cut-offs for the Oral 50g Sucrose Challenge Test and the 13C-Sucrose Breath Test for CSID Cases (Previously Diagnosed Sucraid® Responders) and Controls (GI Asymptomatic Healthy Volunteers) | $12,500 | 0 | 1 |
| SID | $7,483 | 0 | 9 |
| A Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Frequency of Genetic Sucrase-Isomaltase Deficiency Genotypes, and the Efficacy and Safety of Sucraid? (Sacrosidase) Oral Solution in Subjects with Chronic Diarrhea and Sucrase Deficiency | $5,500 | 0 | 2 |
| Prospective Evaluation of the Presence of Sucrose Malabsorption in Patients Referred for Testing for Small Intestinal Bacteria Overgrowth | $3,700 | 0 | 1 |
| A Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Frequency of Genetic Sucrase-Isomaltase Deficiency Genotypes, and the Efficacy and Safety of Sucraid (Sacrosidase) Oral Solution in Subjects with Chronic Diarrhea and Sucrase Deficiency | $500.00 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Daksesh Patel, D.o, D.O | Gastroenterology | Evanston, IL | $303,950 | $0 |
| Stanley Cohen, Md, MD | Pediatric Gastroenterology | Atlanta, GA | $84,598 | $0 |
| Dr. Brooks Cash, Md, MD | Gastroenterology | Houston, TX | $73,015 | $0 |
| Christine Frissora-Rodeo, Md, MD | Internal Medicine | New York, NY | $71,133 | $0 |
| Dr. Maryam Shambayati, D.o, D.O | Pediatrics | Oklahoma City, OK | $65,027 | $0 |
| Dr. William Salt, Md, MD | Gastroenterology | Columbus, OH | $52,862 | $0 |
| Dr. David Lo, M.d, M.D | Internal Medicine | Columbus, OH | $47,146 | $0 |
| Chandar Singaram, Md, MD | Gastroenterology | Sioux Falls, SD | $46,131 | $0 |
| Dr. Jerry Martel, M.d., M.p.h, M.D., M.P.H | Gastroenterology | Miami, FL | $34,127 | $0 |
| Edward Brettholz, Md, MD | Gastroenterology | New York, NY | $27,693 | $0 |
| Dr. Tanaz Danialifar, Md, MD | Pediatrics | Los Angeles, CA | $27,163 | $0 |
| Helena In't Veld, Fnp-C, FNP-C | Family | Avondale, AZ | $27,058 | $0 |
| Fred Fowler, M.d, M.D | Gastroenterology | Charlotte, NC | $24,073 | $0 |
| Felix Rabito, M.d, M.D | Gastroenterology | Covington, LA | $21,962 | $0 |
| Brian Berberian, M.d, M.D | Gastroenterology | Bangor, ME | $17,670 | $0 |
| Enrique Hernandez-Sanchez, M.d, M.D | Pediatric Gastroenterology | Boca Raton, FL | $16,817 | $0 |
| Amana Nasir, M.d, M.D | Pediatric Gastroenterology | Saint Louis, MO | $14,551 | $0 |
| Dr. Jose Quiros, M.d, M.D | Specialist | Charleston, SC | $13,458 | $0 |
| Dr. Devendra Mehta, Md, MD | Pediatric Gastroenterology | Orlando, FL | $11,452 | $0 |
| Ms. Kaitlin Colella, Pa-C, PA-C | Medical | Windermere, FL | $11,122 | $0 |
| Dr. Audrey Woolrich, M.d, M.D | Gastroenterology | New York, NY | $9,660 | $0 |
| Kevin Watson, M.d, M.D | Pediatric Gastroenterology | Akron, OH | $8,587 | $0 |
| Jeffery Lewis, Md, MD | Pediatric Gastroenterology | Atlanta, GA | $7,884 | $0 |
| Mrs. Colleen Nappi, Np, NP | Family | Winchester, VA | $7,618 | $0 |
| Allison Lindstrom, Aprn, APRN | Primary Care | Chicago, IL | $7,527 | $0 |
About QOL Medical, LLC
QOL Medical, LLC has made $6.6M in payments to 13,238 healthcare providers, recorded across 84,171 transactions in the CMS Open Payments database. In 2024, the company paid $1.9M. The top product by payment volume is Sucraid ($3.5M).
Payments were distributed across 138 medical specialties. The top specialty by payment amount is Gastroenterology ($1.4M to 4,811 doctors).
Payment categories include: Food & Beverage ($1.6M), Consulting ($122,688), Research ($3.5M), Travel & Lodging ($75,034).
QOL Medical, LLC is associated with 2 products in the CMS Open Payments database.